Dr Mary Martin was barely retired for four weeks in early 2016 when she was approached by fellow pharmaceutical veteran Eunan Maguire to see if she would be interested in a new position.  After 30 years in drug delivery technology culminating in a senior role with Horizon Therapeutics, a $24 billion Nasdaq-listed firm, Martin was ready for a break. “I announced to my friends and colleagues in Horizon the truth at the time, which was that I intended to retire,” she tells me. “I had even joined the gym.”  But there was something about the excitement in her old friend’s…

Read on for just €1

For a limited time, get your first month for €1 and unlock full access to The Currency and The Wall Street Journal – two premium memberships, one subscription.

Subscribe

Cancel at any time.

Are you already a member? .